Annovis Bio, Inc. (ANVS) stock

ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30

$0.93+0.08 (+9.31%)

Close on Nov 13, 2026Market cap $39.46MP/E –Yield –

Annovis Bio total assets

Total assets on the balance sheet at the end of each period.

Annovis Bio's total assets was $5.50M at Sep 30, 2026. For fiscal 2025 it was $21.08M, up 51.4% from the year before. The highest annual figure on record is $46.00M in fiscal 2021.

Annual total assets

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$21.08M	+51.4%
FY2024	Dec 31, 2024	$13.93M	+36.4%
FY2023	Dec 31, 2023	$10.21M	-71.7%
FY2022	Dec 31, 2022	$36.02M	-21.7%
FY2021	Dec 31, 2021	$46.00M	+466.6%
FY2020	Dec 31, 2020	$8.12M	+626.8%
FY2019	Dec 31, 2019	$1.12M	–

Quarterly total assets

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$5.50M	-68.0%
Q2 FY2026	Jun 30, 2026	$22.04M	+2.7%
Q1 FY2026	Mar 31, 2026	$16.24M	-39.2%
Q4 FY2025	Dec 31, 2025	$21.08M	+51.4%
Q3 FY2025	Sep 30, 2025	$17.19M	+19.7%
Q2 FY2025	Jun 30, 2025	$21.45M	+325.1%
Q1 FY2025	Mar 31, 2025	$26.74M	+242.2%
Q4 FY2024	Dec 31, 2024	$13.93M	+36.4%
Q3 FY2024	Sep 30, 2024	$14.36M	+40.5%
Q2 FY2024	Jun 30, 2024	$5.05M	-77.9%
Q1 FY2024	Mar 31, 2024	$7.81M	-69.4%
Q4 FY2023	Dec 31, 2023	$10.21M	-71.7%
Q3 FY2023	Sep 30, 2023	$10.22M	-72.5%
Q2 FY2023	Jun 30, 2023	$22.82M	-42.9%
Q1 FY2023	Mar 31, 2023	$25.55M	-42.1%
Q4 FY2022	Dec 31, 2022	$36.02M	-21.7%
Q3 FY2022	Sep 30, 2022	$37.12M	-22.1%
Q2 FY2022	Jun 30, 2022	$39.97M	-19.3%
Q1 FY2022	Mar 31, 2022	$44.10M	+639.3%
Q4 FY2021	Dec 31, 2021	$46.00M	+466.6%
Q3 FY2021	Sep 30, 2021	$47.65M	+406.8%
Q2 FY2021	Jun 30, 2021	$49.50M	+385.2%
Q1 FY2021	Mar 31, 2021	$5.96M	-47.9%
Q4 FY2020	Dec 31, 2020	$8.12M	+626.8%
Q3 FY2020	Sep 30, 2020	$9.40M	–
Q2 FY2020	Jun 30, 2020	$10.20M	–
Q1 FY2020	Mar 31, 2020	$11.44M	–
Q4 FY2019	Dec 31, 2019	$1.12M	–